Department of Medicine and the Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Data Analysis & Research, Office of Data Management & Information Systems, West Virginia Department of Education, Charleston, WV 25305, USA.
J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3273-e3280. doi: 10.1210/clinem/dgac285.
Decreased first-phase insulin response (FPIR) during intravenous glucose tolerance testing (IVGTT) is an early indicator of β-cell dysfunction and predictor of type 1 diabetes (T1D).
Assess whether oral glucose tolerance test (OGTT) measures could serve as FPIR alternatives in their ability to predict T1D in autoantibody positive (Aab+) subjects.
OGTT and IVGTT were performed within 30 days of each other. Eleven OGTT variables were evaluated for (1) correlation with FPIR and (2) T1D prediction.
Type 1 Diabetes TrialNet "Oral Insulin for Prevention of Diabetes in Relatives at Risk for T1D" (TN-07) and Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) studies clinical sites.
TN-07 (n = 292; age 9.4 ± 6.1 years) and DPT-1 (n = 194; age 15.1 ± 10.0 years) Aab + relatives of T1D individuals.
(1) Correlation coefficients of OGTT measures with FPIR and (2) T1D prediction at 2 years using area under receiver operating characteristic (ROCAUC) curves.
Index60 showed the strongest correlation in DPT-1 (r = -0.562) but was weaker in TN-07 (r = -0.378). C-peptide index consistently showed good correlation with FPIR across studies (TN-07, r = 0.583; DPT-1, r = 0.544; P < 0.0001). Index60 and C-peptide index had the highest ROCAUCs for T1D prediction (0.778 vs 0.717 in TN-07 and 0.763 vs 0.721 in DPT-1, respectively; P = NS), followed by FPIR (0.707 in TN-07; 0.628 in DPT-1).
C-peptide index was the strongest measure to correlate with FPIR in both studies. Index60 and C-peptide index had the highest predictive accuracy for T1D and were comparable. OGTTs could be considered instead of IVGTTs for subject stratification in T1D prevention trials.
静脉葡萄糖耐量试验(IVGTT)期间胰岛素第一时相分泌反应(FPIR)降低是β细胞功能障碍的早期指标,也是 1 型糖尿病(T1D)的预测指标。
评估口服葡萄糖耐量试验(OGTT)指标是否可以替代 FPIR,用于预测自身抗体阳性(Aab+)受试者中的 T1D。
OGTT 和 IVGTT 在彼此 30 天内进行。评估了 11 个 OGTT 变量,以(1)与 FPIR 的相关性和(2)T1D 预测。
1 型糖尿病试验网(TrialNet)“口服胰岛素预防高危 T1D 亲属的糖尿病”(TN-07)和糖尿病预防试验-1 型糖尿病(DPT-1)研究临床站点。
TN-07(n=292;年龄 9.4±6.1 岁)和 DPT-1(n=194;年龄 15.1±10.0 岁)Aab+T1D 个体的亲属。
(1)OGTT 指标与 FPIR 的相关系数和(2)使用接受者操作特征(ROC)曲线下面积(AUC)的 2 年 T1D 预测。
在 DPT-1 中,Index60 相关性最强(r=-0.562),但在 TN-07 中较弱(r=-0.378)。C 肽指数在两项研究中均与 FPIR 有良好的相关性(TN-07,r=0.583;DPT-1,r=0.544;P<0.0001)。Index60 和 C 肽指数对 T1D 预测的 AUC 值最高(TN-07 中分别为 0.778 与 0.717,DPT-1 中分别为 0.763 与 0.721;P=NS),其次是 FPIR(TN-07 中为 0.707;DPT-1 中为 0.628)。
在两项研究中,C 肽指数与 FPIR 的相关性最强。Index60 和 C 肽指数对 T1D 具有最高的预测准确性,且相当。OGTT 可考虑替代 IVGTT 用于 T1D 预防试验中的受试者分层。